Novartis AG Says Cancer Drug Kymriah Study Shows Efficacy, Safety

Date : 12/09/2019 @ 9:30PM
Source : Dow Jones News
Stock : Novartis AG (NVS)
Quote : 90.08  -6.68 (-6.90%) @ 1:00AM
After Hours
Last Trade
Last $ 89.89 ▼ -0.19 (-0.21%)

Novartis AG Says Cancer Drug Kymriah Study Shows Efficacy, Safety

Novartis (NYSE:NVS)
Historical Stock Chart

3 Months : From Nov 2019 to Feb 2020

Click Here for more Novartis Charts.
   By Maria Armental 
 

Novartis AG said its cancer drug Kymriah showed consistent efficacy and safety outcomes when used in real-world settings on a broader group of U.S. patients.

The analyses are from a readout of a 15-year post-marketing study looking at Kymriah in adults with relapsed or refractory diffuse large B cell lymphoma, the most common type of lymphoma, and in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Kymriah (tisagenlecleucel), which company officials expect to reach blockbuster potential over the next five years, is part of a type of therapies known as Car-T that use genetically engineered T-cells to attack the blood cancer.

 

Write to Maria Armental at maria.armental@wsj.com

 

(END) Dow Jones Newswires

December 09, 2019 16:15 ET (21:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest NVS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.